Targeting PD-L1 on tumor cells
AssigneeMayo Foundation for Medical Education and Research
InventorsStephen James Russell, Autumn J. Schulze, Arun Ammayappan, Kah-Whye Peng, Camilo Ayala Breton
Life of this patent
Estimating the term…
Abstract
This document relates to materials and methods for treating cancer. For example, this document provides materials and methods for using PD-L1 targeting domains in bispecific chimeric polypeptides, chimeric transmembrane polypeptides, genetically modified viruses, nucleic acid vectors, and/or fusion-inducing cells to treat cancer.
Claims16
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1, wherein the PD-L1 targeting domain comprises an antibody single-chain variable fragment, wherein the antibody single-chain variable fragment comprises an amino acid sequence encoded by a nucleotide sequence having at least 90% identity to the nucleotide sequence of SEQ ID NO:1.
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1, wherein the PD-L1 targeting domain comprises an antibody single-chain variable fragment, wherein the antibody single-chain variable fragment comprises an amino acid sequence encoded by a nucleotide sequence having at least 90% identity to the nucleotide sequence of SEQ ID NO:2.
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1, wherein the effector domain comprises an antibody single-chain variable fragment that binds a CD3 polypeptide, wherein the chimeric polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6.
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1, wherein the effector domain comprises an antibody single-chain variable fragment that binds a CD3 polypeptide, wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:6.
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1, wherein the effector domain comprises an antibody single-chain variable fragment that binds a CD3 polypeptide, wherein the chimeric polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:8.
A method for treating cancer in a mammal, wherein said method comprises administering a genetically modified virus that expresses a chimeric polypeptide comprising a PD-L1 targeting domain and an effector domain on its surface under conditions wherein the virus is capable of infecting a cancer cell expressing PD-L1, wherein the effector domain comprises an antibody single-chain variable fragment that binds a CD3 polypeptide, wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:8.
Dependencies are inferred from the claim text.